{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:35:58Z","timestamp":1794274558090,"version":"4.9.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Immunovant, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2023,11,8]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Batoclimab, a fully human monoclonal antibody that inhibits the neonatal fragment crystallisable receptor, has shown promising phase 2 clinical trial results in patients with generalised myasthenia gravis (gMG).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>In this phase 3, randomised, quadruple-blind, placebo-controlled study, adults with gMG will be randomised 1:1:1 to induction therapy with batoclimab 680 mg, batoclimab 340 mg, or placebo, administered once weekly (QW) for 12 weeks as a subcutaneous injection. The primary endpoint is the change from baseline to week 12 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Batoclimab-treated patients achieving a \u22652-point improvement from baseline on MG-ADL at week 10 or week 12 will be re-randomised to maintenance treatment with batoclimab 340 mg QW, batoclimab 340 mg every other week (Q2W), or placebo for 12 weeks; batoclimab-treated patients with a &lt;2-point improvement at week 10 and week 12 will be switched to placebo for the maintenance period and discontinued thereafter. Placebo-treated patients from the induction period will be re-randomised to batoclimab 340 mg QW or Q2W in the maintenance period. All patients who complete the maintenance period and achieve a \u22652-point improvement from baseline in MG-ADL during \u22651 of the final 2 visits of the induction and\/or maintenance periods will continue their current batoclimab dose (or switch to batoclimab 340 mg QW for those on placebo) for a 52-week long-term extension (LTE-1). Patients who complete LTE-1 may enter a second, optional 52-week LTE (LTE-2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This trial is being conducted in accordance with the International Council for Harmonisation Guideline for Good Clinical Practice, the Declaration of Helsinki, and each site\u2019s Institutional Review Board\/Independent Ethics Committee. All patients must provide written informed consent. Results from this study will be published in peer-reviewed journals and presented at national and global conferences.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05403541\">NCT05403541<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2023-000536","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T13:16:54Z","timestamp":1704892614000},"page":"e000536","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial"],"prefix":"10.1136","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct05403541","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05403541","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03863080","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03863080","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05517447","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05517447","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05524571","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05524571","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05517421","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05517421","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05581199","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05581199","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03922321","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03938545","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03938545","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05039190","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05039190","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04650854","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04650854","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04951622","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04951622","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-5135","authenticated-orcid":false,"given":"Michael","family":"Benatar","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[{"name":"Department of Neurology with Institute of Translational Neurology, University of M\u00fcnster, M\u00fcnster, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Immunovant, Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Macias","sequence":"additional","affiliation":[{"name":"Immunovant, Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2025072811445728000_6.1.e000536.1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"2025072811445728000_6.1.e000536.2","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1007\/s00415-022-11290-w","article-title":"Burden of disease in myasthenia gravis: taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"2025072811445728000_6.1.e000536.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.011"},{"key":"2025072811445728000_6.1.e000536.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124"},{"key":"2025072811445728000_6.1.e000536.5","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000002790"},{"key":"2025072811445728000_6.1.e000536.6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2214\/ajr.102.3.530","article-title":"Sequential chemotherapy and radiation therapy of Buccal mucosa carcinoma in South India: methods and preliminary results","volume":"102","author":"Von Essen","year":"1968","journal-title":"American Journal of Roentgenology"},{"key":"2025072811445728000_6.1.e000536.7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5694\/j.1326-5377.1976.tb117617.x","article-title":"CRAB\u201d care and cancer chemotherapy","volume":"2","author":"Stephens","year":"1976","journal-title":"Med J Aust"},{"key":"2025072811445728000_6.1.e000536.8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000323","article-title":"Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials","volume":"2","author":"Emamikia","year":"2016","journal-title":"RMD Open"},{"key":"2025072811445728000_6.1.e000536.9","doi-asserted-by":"crossref","first-page":"104518","DOI":"10.1016\/j.msard.2023.104518","article-title":"Efficacy and safety of repeated low-dose Rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study","volume":"70","author":"Zhao","year":"2023","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"2025072811445728000_6.1.e000536.10","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s00415-019-09296-y","article-title":"Rituximab as induction therapy in refractory myasthenia gravis: 18-month follow-up study","volume":"266","author":"Singh","year":"2019","journal-title":"J Neurol"},{"key":"2025072811445728000_6.1.e000536.11","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01175-7"},{"key":"2025072811445728000_6.1.e000536.12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting Fcrn for Immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025072811445728000_6.1.e000536.13","unstructured":"VYVGART\u00ae (efgartigimod alfa-fcab) injection for intravenous use . Prescribing information. Argenx BV. 2022. Available: https:\/\/www.argenx.com\/product\/vyvgart-prescribing-information.pdf [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.14","unstructured":"RYSTIGGO\u00ae (rozanolixizumab-noli) injection for subcutaneous use . Prescribing information. UCB, Inc; 2023. Available: https:\/\/www.ucb-usa.com\/RYSTIGGO-prescribing-information.pdf [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.15","unstructured":"Immunovant Sciences . A study of RVT-1401 in myasthenia gravis (MG) patients. Clinicaltrials.Gov Identifier: Nct03863080 . 2021. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03863080 [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.16","unstructured":"Immunovant Sciences . Extension study to assess Batoclimab in participants with thyroid eye disease. Clinicaltrials.Gov Identifier: Nct05517447 . 2023. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05517447 [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.17","unstructured":"Immunovant Sciences . Study to assess Batoclimab in participants with active thyroid eye disease. Clinicaltrials.Gov Identifier: Nct05524571 . 2023. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05524571 [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.18","unstructured":"Immunovant Sciences . Study to assess Batoclimab in participants with active thyroid eye disease (B). Clinicaltrials.Gov Identifier: Nct05517421 . 2023. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05517421 [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.19","unstructured":"Immunovant Sciences GmbH . To assess efficacy and safety of Batoclimab in adult participants with active CIDP. Nct05581199 . n.d. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05581199"},{"key":"2025072811445728000_6.1.e000536.20","unstructured":"Immunovant Sciences . Study of RVT-1401 for the treatment of patients with moderate to severe active graves. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03922321 [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.21","unstructured":"Immunovant Sciences . ASCEND GO-2: study of RVT-1401 for the treatment of participants with active, moderate to severe graves\u2019 Ophthalmopathy (GO). Clinicaltrials.Gov Identifier: Nct03938545 . 2022. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03938545 [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.22","doi-asserted-by":"crossref","unstructured":"Nowak RJ , Breiner A , Bril V , et al . Subcutaneous batoclimab in generalized myasthenia gravis: results from a phase 2a trial with an open-label extension. Ann Clin Transl Neurol 2023;Dec 7. doi:10.1002\/acn3.51946 [Epub ahead of print Online ahead of print].","DOI":"10.1002\/acn3.51946"},{"key":"2025072811445728000_6.1.e000536.23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of Batoclimab in Chinese patients with generalized myasthenia gravis: A double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol Ther"},{"key":"2025072811445728000_6.1.e000536.24","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9"},{"key":"2025072811445728000_6.1.e000536.25","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","article-title":"Proof-of-concept and randomized, placebo-controlled trials of an Fcrn inhibitor, Batoclimab, for thyroid eye disease","volume":"108","author":"Kahaly","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025072811445728000_6.1.e000536.26","unstructured":"Harbour Biomed ANNOUNCES positive Topline results from phase III trial of Batoclimab for treatment of generalized myasthenia gravis. 2023. Available: https:\/\/www.harbourbiomed.com\/news\/207.html [Accessed 24 Oct 2023]."},{"key":"2025072811445728000_6.1.e000536.27","unstructured":"Harbour BioMed (Guangzhou) Co., Ltd . Evaluate the efficacy and safety of Hbm9161(Hl161) subcutaneous injection in patients with generalized MG patients (MG). Clinicaltrials.Gov Identifier: Nct05039190 . 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT05039190 [Accessed 24 Oct 2023]."},{"issue":"23_Supplement_2","key":"2025072811445728000_6.1.e000536.28","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000903328.46907.49","article-title":"Vivacity MG phase 3 study: clinical trial of Nipocalimab administered to adults with generalized myasthenia gravis","volume":"99","author":"Ramchandren","year":"2022","journal-title":"Neurology"},{"key":"2025072811445728000_6.1.e000536.29","unstructured":"UCB Biopharma SRL . A study to evaluate Rozanolixizumab in study participants with generalized myasthenia gravis. Clinicaltrials.Gov Identifier: Nct04650854 . 2023. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04650854"},{"key":"2025072811445728000_6.1.e000536.30","unstructured":"A study of Nipocalimab administered to adults with generalized myasthenia gravis. Clinicaltrials.Gov Identifier: Nct04951622 . 2023. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04951622 [Accessed 24 Oct 2023]."}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2023-000536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:45:07Z","timestamp":1753728307000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2023-000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjno-2023-000536"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2023-000536","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}